Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ixazomib (MLN2238) 含硼肽蛋白酶体抑制剂(PI),可抑制 20S 蛋白酶体的糜蛋白酶样蛋白水解 (β5) 位点,IC50为 3.4 nM,Ki 为 0.93 nM。它还抑制半胱天冬酶样 (β1) 和胰蛋白酶样 (β2) 蛋白水解位点,IC50值为 31和3500 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 222 | 现货 | ||
5 mg | ¥ 495 | 现货 | ||
10 mg | ¥ 747 | 现货 | ||
25 mg | ¥ 1,490 | 现货 | ||
50 mg | ¥ 2,230 | 现货 | ||
100 mg | ¥ 3,350 | 现货 | ||
500 mg | ¥ 7,320 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 547 | 现货 |
产品描述 | Ixazomib (MLN2238) , a second generation, boron-containing peptide proteasome inhibitor (PI), inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome (IC50/Ki: 3.4/0.93 nM, in cell-free assays), also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites (IC50: 31/3500 nM). |
靶点活性 | 20S proteasome:0.93 nM(Ki), 20S proteasome:3.4 nM, Caspase-like β1:31nM, Trypsin like β2:3500 nM |
体外活性 | MLN2238对CWR22移植瘤具有抗癌活性.在WSU-DLCL2移植瘤模型中,MLN2238的肿瘤药效反应比bortezomib更强. 此外,在OCI-Ly10和PHTX22L模型中,MLN2238比 bortezomib具有更高的药效和抗癌活性.作用于移植瘤时,MLN2238的药效反应比bortezomib更较强,且其最大值更高,对肿瘤蛋白酶的抑制效果更持久. |
体内活性 | MLN2238是MLN9708的生物活性代谢物。MLN2238和Bortezomib均为时间依赖性的蛋白酶体可逆抑制剂,但与Bortezomib(110分钟)相比,MLN2238(18分钟)作用于蛋白酶体的分离半衰期要快6倍。MLN2238的肿瘤药效 要高于Bortezomib。MLN2238是氮端加帽的二肽亮氨酸硼酸,对20S 蛋白酶体中糜蛋白酶类的水解位点有抑制作用(IC50/Ki:3.4/0.93 nM)。更高浓度时,MLN2238对20S蛋白酶体的caspase类水解位点(IC50:31 nM)和胰蛋白酶类水解位点(IC50:3.5 μM)也有抑制作用。MLN2238抑制Calu-6细胞(IC50:9.7 nM)。 |
激酶实验 | Kinase assay : Calu-6 cells are cultured in MEM containing 10% fetal bovine serum and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. Proteasome activity is assessed by monitoring hydrolysis of the chymotrypsin-like substrate Suc-LLVY-aminoluciferin in the presence of luciferase using the Proteasome-Glo assay reagents according to the manufacturer's instructions. Luminescence is measured using a LEADseeker instrument. |
细胞实验 | Calu-6 cells are cultured in MEM containing 10% FBS and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. For IC50 determinations, cells are treated with varying concentrations of Bortezomib or MLN2238 in DMSO (0.5% final, v/v) for 1 hour at 37 °C. For reversibility experiments, cells are treated with either 1 μM Bortezomib or MLN2238 for 30 minutes at 37 °C and then washed thrice in medium to remove the Bortezomib or MLN2238. Cells are incubated for an additional 4 hours at 37 °C, after which the medium is removed and replaced with fresh medium. (Only for Reference) |
别名 | 艾沙佐米, MLN2238 |
分子量 | 361.03 |
分子式 | C14H19BCl2N2O4 |
CAS No. | 1072833-77-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 67 mg/mL (185.6 mM)
Ethanol: 9 mg/mL (24.92 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.7699 mL | 13.8493 mL | 27.6985 mL | 69.2463 mL |
5 mM | 0.554 mL | 2.7699 mL | 5.5397 mL | 13.8493 mL | |
10 mM | 0.277 mL | 1.3849 mL | 2.7699 mL | 6.9246 mL | |
20 mM | 0.1385 mL | 0.6925 mL | 1.3849 mL | 3.4623 mL | |
DMSO | 50 mM | 0.0554 mL | 0.277 mL | 0.554 mL | 1.3849 mL |
100 mM | 0.0277 mL | 0.1385 mL | 0.277 mL | 0.6925 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ixazomib 1072833-77-2 Apoptosis Autophagy Proteases/Proteasome Ubiquitination Proteasome Caspase 艾沙佐米 Inhibitor MLN2238 MLN-2238 MLN 2238 inhibit inhibitor